Anastrozole prevents recurrence more than tamoxifen in some with noninvasive breast cancer

Anastrozole provides a significant benefit compared with tamoxifen in preventing recurrence after a lumpectomy and radiation therapy in postmenopausal women ages 60 years or younger who had DCIS (ductal carcinoma in situ), a common diagnosis of non-invasive breast cancer. In women over age 60, it works as well as tamoxifen. The benefit reported in this trial appeared later in follow up of the women in the study.
Source: ScienceDaily Headlines - Category: Science Source Type: news

Related Links:

Approximately 60,000 women in the United States are diagnosed with ductal carcinoma in situ (DCIS) annually.1 Although DCIS is both a precursor and risk factor for development of invasive breast cancer (IBC), survival after treatment of DCIS is very high regardless of treatment approach.2 After lumpectomy, radiation therapy (RT) decreases local recurrence rates by 50% relatively but has no apparent impact on distant metastases or survival.2 Breast preservation and prevention of local recurrence, either in the form of DCIS or invasive cancer, is thus the primary oncologic benefit of RT in patients who received a diagnosis of DCIS.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Feature Source Type: research
ConclusionThe HF schedule with CB in DCIS patients is well tolerated and associated with excellent clinical outcomes. This schedule affords the benefit of delivering higher dose to the lumpectomy site without protracting overall treatment time.
Source: Journal of Radiation Oncology - Category: Cancer & Oncology Source Type: research
AbstractTreatment for ductal carcinoma in-situ (DCIS) has historically been extrapolated from studies of invasive breast cancer. Accepted local therapy approaches range from small local excisions, with or without radiation, to bilateral mastectomies. Systemic treatment with endocrine therapy is often recommended for hormone positive patients. With improvements in imaging, pathologic review, and treatment techniques in the modern era, combined with new information regarding tumor biology, the management of DCIS is rapidly evolving. A multidisciplinary approach to treatment is now more important than ever, with a shift towar...
Source: Journal of Mammary Gland Biology and Neoplasia - Category: Cancer & Oncology Source Type: research
(JAMA Network) Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone   in women   with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
In this study, we sought to evaluate the outcomes for patients diagnosed with DCIS treated using accelerated whole breast RT and concomitant lumpectomy boost following breast conserving surgery.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Oral Abstract Source Type: research
The appropriate negative margin width for women undergoing breastā€conserving surgery for both ductal carcinoma in situ (DCIS) and invasive carcinoma is controversial. This review examines the available data on the margin status for invasive breast cancer and DCIS, and highlights the similarities and differences in tumor biology and standard treatments that affect the local recurrence (LR) risk and, therefore, the optimal surgical margin. Consensus guidelines support a negative margin, defined as no ink on tumor, for invasive carcinoma treated with breastā€conserving therapy. Because of differences in the growth pattern ...
Source: Cancer - Category: Cancer & Oncology Authors: Tags: Review Article Source Type: research
ConclusionsAlthough HF-WBI can save 3  weeks of patient time, its adoption remained low in the US. There was only a slight increase in the overall use of radiotherapy among patients undergoing lumpectomy.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsEarly results from this multi-center trial demonstrate that IORT using the Xoft Axxent eBx System at the time of breast conservation surgery continues to be a promising treatment option for early stage breast cancer. The short course of radiation therapy for select patients has excellent to good cosmetic results and a low rate of high-grade adverse events and recurrences.FundingFunded by Xoft, Inc., a subsidiary of iCAD, Inc.AcknowledgementMedical writing support from Dr. Theresa E. Singleton, Singleton Science, LLC.Citation Format: Gampenrieder SP, Rinnerthaler G, Pulverer W, Weinhäusel A, Hufnagl C, Hackl...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
ConclusionsEarly results from this multi-center trial suggest that IORT as a tumor-bed boost using the Xoft Axxent eBx System at the time of breast conservation surgery is safe and has low morbidity. To date, the majority of participants receiving an unplanned IORT boost have had excellent to good cosmetic results and the majority of adverse events have been low-grade.FundingFunded by Xoft, Inc., a subsidiary of iCAD, Inc.Citation Format: Kasimir-Bauer S, Bittner A-K, Goebel A, Hoffmann O, Browne AJ, Rauner M, Hofbauer LC, Wimberger P, Kimmig R, Rachner TD. Serum levels of RANKL are increased in primary breast cancer patie...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
Objectives: To describe observations of one-year follow-up of subjects treated on a multi-center, non-randomized study with a single fraction of intra-operative radiation therapy (IORT) using the Xoft® Axxent® Electronic Brachytherapy System® (eBx®) immediately following surgical resection of early stage breast cancer.Methods: Two-hundred forty three (243) subjects were treated at seventeen (17) US hospitals. Upon meeting the inclusion/exclusion criteria, patients underwent partial mastectomy, placement of a balloon applicator suitable to the surgical bed in the lumpectomy cavity and inflated with saline (3...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research
More News: Arimidex | Breast Cancer | Breast Carcinoma | Breast Lumpectomy | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | Lumpectomy | Radiation Therapy | Science | Study | Tamoxifen | Women